Literature DB >> 34243811

Pulmonary coinfection of Mycobacterium tuberculosis and Tropheryma whipplei: a case report.

Binghua Zhu1, Jing Tang2, Rong Fang1, Xuejie Fei1, Qing Wang1, Wenqing Wang1, Xueqin Wu3, Chao Liu4, Qian Wang5.   

Abstract

BACKGROUND: We diagnosed a clinical case of pulmonary infection involving Mycobacterium tuberculosis and Tropheryma whipplei in a patient with acute respiratory distress syndrome. The diagnosis was assisted by metagenomic next-generation sequencing of bronchoalveolar lavage fluid. CASE
PRESENTATION: A 44-year-old Han Chinese inmate was transferred to the emergency department because of dry cough, chest tightness, and shortness of breath. The patient's body temperature rose to 39.3 °C following empirical cephalosporin treatment for 1 week. The blood CD4+/CD8+ ratio was 0.7, suggesting immunodeficiency. Routine microbiological tests were performed, and tuberculosis interferon gamma release assays were positive. Mycobacterium tuberculosis polymerase chain reaction was also positive. Chest computed tomography scan revealed miliary nodules and ground-glass opacifications, which were in accordance with tuberculosis. To fully examine the etiology, we performed routine laboratory tests and metagenomic sequencing, the results of which indicated the presence of Mycobacterium tuberculosis and Tropheryma whipplei. We administered anti-tuberculosis regimen in combination with trimethoprim/sulfamethoxazole. The patient recovered, with chest computed tomography scan showing absorption of lesions.
CONCLUSIONS: Compared with traditional diagnostic methods such as culture and serology, metagenomic next-generation sequencing has the advantage of detecting a wide array of microorganisms in a single test and therefore can be used for clinical diagnosis of rare pathogens and microbial coinfections. It is particularly useful for immunocompromised patients as they are more prone to infection by opportunistic microorganisms.
© 2021. The Author(s).

Entities:  

Keywords:  Metagenomic next-generation sequencing; Mycobacterium tuberculosis; Pulmonary infection; Tropheryma whipplei

Mesh:

Year:  2021        PMID: 34243811      PMCID: PMC8269402          DOI: 10.1186/s13256-021-02899-y

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


Background

Here we review a case of community-acquired pneumonia caused by Mycobacterium tuberculosis (MTB) and Tropheryma whipplei (TW). MTB is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis [1]. TW is a Gram-positive Actinobacteria and the causative agent of Whipple’s disease [2]. TW is commonly found in the environment and can be carried by 1.5–7% of healthy individuals without causing symptoms [3]. MTB may occur concomitantly with other infections such as human immunodeficiency virus (HIV) [4]. However, clinical reports of MTB and TW coinfection are scarce.

Case presentation

A 44-year-old male patient (Han Chinese ethnicity) experienced dry cough, chest tightness, and shortness of breath for 2 weeks and was transferred to the emergency department at Shuguang Hospital. The patient has been previously diagnosed with type 2 diabetes and hepatitis C and had a history of intravenous drug use. Upon admission, we conducted a physical examination that showed a body temperature of 39.3 °C, pulse of 117 beats per minute, respiratory rate of 22–30 breaths per minute, and blood pressure of 120/84 mmHg. The patient had normal development and body shape, and was conscious but showed signs of malnutrition. Skin was normal without yellow dye, erythema, rash, or pigmentation. Lymph glands were not enlarged. Chest auscultation indicated rough breath sounds and moist rales in both lungs. Furthermore, bronchoscopy and chest computed tomography (CT) scan revealed miliary nodules and ground-glass opacifications in both lungs (Fig. 1a, b).
Fig. 1

Bronchoscopy and chest computed tomography image. a. Images taken during bronchoscopy showing miliary nodules. b. Chest computed tomography image showing ground-glass opacifications in both lungs

Bronchoscopy and chest computed tomography image. a. Images taken during bronchoscopy showing miliary nodules. b. Chest computed tomography image showing ground-glass opacifications in both lungs Next, we carried out routine laboratory tests, and the results were as follows: SpO2 90% (breath via facial mask, FiO2 50%), PaO2 52 mmHg, PaCO2 26 mmHg, pH 7.5, Base Excess (BE) 0.6 mmol/L, Lactate concentration (Lac) 2.1 mmol/L, Oxygenation Index (OI) 101 mmHg, white blood cell count (WBC) 7.3 × 109/L, Neutrophil (N) 89%, C-reactive protein (CRP) 111.7 mg/L, procalcitonin (PCT) 0.67 ng/ml, total bilirubin (TBiL) 31.8 μmol/L, alanine aminotransferase (ALT) 59 U/L, aspartate aminotransferase (AST) 135 U/L, albumin (Alb) 24 g/L, and CD4+/CD8+ 0.7. The microbiological culture of sputum reported Gram-positive and Gram-negative cocci and Candida albicans. Acid-fast stain, Mycoplasma pneumoniae tests were negative. Bacterial and fungal culture of bronchoalveolar lavage fluid (BALF) were negative. Galactomannan test (GM test) using BALF was negative. Blood culture was negative. Serum β-d-Glucan test (G test) was negative. Tuberculosis immunoglobulin M (IgM) and immunoglobulin G (IgG) tests were negative. However, the interferon alpha release assays including T-SPOT.TB and QuantiFERON-TB Gold (QFT-G) were positive. As a result, we performed metagenomic next-generation sequencing (mNGS) tests on BALF (DNA sequencing), which reported one read of Mycobacterium tuberculosis and 43 reads of Tropheryma whipplei. To further confirm the presence of MTB, we carried out MTB fluorescent polymerase chain reaction (PCR) test, which was positive for MTB with no detection of rifampicin and isoniazid antibiotic resistance (Table 1).
Table 1.

Results of MTB fluorescent PCR

TestMolecular targetResult
MTBrpoB genePositive
Rifampicin resistancerpoB AA 507-512 mutationNegative
rpoB AA 512-520 mutationNegative
rpoB AA 520-528 mutationNegative
rpoB AA 528-533 mutationNegative
Isoniazid resistancekatG (315 G>C)GG
katG (−15 C>T)CC

MTB: Mycobacterium Tuberculosis, AA: amino acid

Results of MTB fluorescent PCR MTB: Mycobacterium Tuberculosis, AA: amino acid Combining clinical manifestation and above-mentioned microbiological data, we diagnosed the patient with community-acquired pneumonia with acute respiratory distress syndrome (ARDS) that was caused by coinfection of MTB and TW. We then performed endotracheal intubation and mechanical ventilation and administered trimethoprim/sulfamethoxazole (TMP/SMX) 1.44 g three times per day orally, isoniazid 0.3 g once per day orally, rifapentine 0.6 g twice per week orally, amikacin 0.6 once per day intravenous guttae (ivgtt), and ethambutol 0.75 g once per day orally. After 14 days of treatment, the patient’s body temperature returned to normal with improvement of blood oxygen saturation. Chest CT scan displayed absorption of ground-glass opacifications (Fig. 2a). Ventilator was removed, and the patient was given high-flow nasal cannula. At 21 days posttreatment, chest CT scan showed significant absorption of miliary nodules (Fig. 2b).
Fig. 2

Chest computed tomography images after treatment. a. Chest computed tomography after 14 days of treatment. b. Chest computed tomography after 21 days of treatment

Chest computed tomography images after treatment. a. Chest computed tomography after 14 days of treatment. b. Chest computed tomography after 21 days of treatment

Discussion and conclusions

Tuberculosis may lead to severe sepsis, which can be fatal in patients with immunodeficiency, including patients with HIV, cancer, and immunological disorders [5]. TW could cause both acute and chronic infections and can colonize healthy individuals. On the other hand, TW is known to cause acute pneumonia, which was previously reported to be associated with aspiration pneumonia as well as acute respiratory distress syndrome (ARDS) [6]. TW infection may initially lead to fever and idiopathic or migratory arthritis and progress to cause steatorrhea, weight loss, hepatosplenomegaly, and ascites. Notably, approximately 30% of TW infection affects the lung, resulting in respiratory symptoms including dry cough, chest pain, shortness of breath, and pleural adhesion. There are at least 11 clinical reports involving TW and interstitial lung disease [7]. In a study using mNGS and BALF samples collected from 210 intensive care unit (ICU) patients with pneumonia, six (3%) contained sequencing reads specifically aligned to TW [8]. In addition, TW is commonly found in HIV patients, who have poses a higher risk of pulmonary infection [9]. Considering that pulmonary alveoli contain macrophages, which TW mainly targets, they may serve as primary sites of TW colonization or infection. Diagnosis of TW is usually difficult owing to the paucity of microbiological tests. The antibody titer is low in serum, making a serology test ineffective at diagnosing TW infection [10]. Periodic acid–Schiff (PAS) stain has been a traditional and primary diagnostic method for TW. However, the presence of other pathogens including Pneumocystis jirovecii and Mycobacterium avium may produce false-positive results [11]. Moreover, TW is auxotrophic and takes ~18 hours for one proliferation cycle, making bacterial culture impractical. However, with the development of nucleic acid tests, PCR-based and sequencing-based molecular assays have proven to be effective for TW detection and, hence, have become the main diagnostic choice [12]. Guidelines for treating TW infection are currently lacking. Literature suggests a variety of antimicrobial regimen, including penicillin 12,000 units/day [13], tetracycline 600 mg/day [14], TMP/SMX 160/800 mg/day [15], TMP/SMX 160/800 mg/day with ceftriaxone 2 g/day or meropenem 3 g/day [16], and doxycycline 200 mg/day with hydroxychloroquine 600 mg/day [15]. In our case, the patient has type 2 diabetes and has been serving a sentence in prison. According to one study, the incidence rate of MTB infection in prison (657/100,000) is 3.75-fold higher than in the general population [17]. The malnutrition state, positive for blood T-SPOT.TB and QFT-G tests, as well as miliary nodules seen on chest CT were all consistent with tuberculosis. The diagnosis was further corroborated by mNGS and PCR. The low read number may be due to difficulties in nucleic acid extraction, as the cell walls of MTB are rich in lipid and hard to break by either chemical or physical means. In addition to miliary nodules, ground-glass opacifications were also evident on chest CT that indicate infection of additional pathogens. The ratio of CD4+/CD8+ was less than 1, suggesting an immunodeficient state of the patient. We initially did not administer anti-TB treatment but were able to observe some absorption of exudation around miliary nodules after use of antibiotics. By adding anti-TB therapy, most pulmonary lesions were absorbed within 3 weeks (Fig. 2b). Moreover, we ruled out pulmonary alveolar hemorrhage and proteinosis because of the following evidence: (1) blood was not present in BALF; (2) the patient has been diagnosed with hepatitis C, which was classified as Child–Pugh class A with normal international normalized ratio (INR); (3) BALF was clear, and no precipitates were seen after centrifugation; and (4) PAS stain was negative. As a result, combining these clinical observations with presence of MTB and TW sequencing reads by mNGS, we concluded that the patient had a pulmonary coinfection of MTB and TW. In summary, TW is less commonly detected in the general population than in immunocompromised individuals. Opportunistic infection and coinfection of TW is possible. Pulmonary TW infection is usually indistinguishable from other bacterial infections. As a result, nucleic acid tests such as mNGS are especially valuable for identification and differential diagnosis of TW infection. We also confirmed in our case that oral administration of TMP/SMX was effective in treating pulmonary TW infection.
  17 in total

1.  AIDS with Mycobacterium avium-intracellulare lesions resembling those of Whipple's disease.

Authors: 
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

2.  Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe.

Authors:  Stephen V Gordon; Tanya Parish
Journal:  Microbiology       Date:  2018-02-21       Impact factor: 2.777

Review 3.  Whipple's disease.

Authors:  Xavier Puéchal
Journal:  Ann Rheum Dis       Date:  2013-01-03       Impact factor: 19.103

4.  Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus.

Authors:  B La Scola; F Fenollar; P E Fournier; M Altwegg; M N Mallet; D Raoult
Journal:  Int J Syst Evol Microbiol       Date:  2001-07       Impact factor: 2.747

Review 5.  New insights into Whipple's disease and Tropheryma whipplei infections.

Authors:  Benoit Desnues; Khatoun Al Moussawi; Florence Fenollar
Journal:  Microbes Infect       Date:  2010-08-11       Impact factor: 2.700

Review 6.  Whipple disease revealed by lung involvement: a case report and literature review.

Authors:  Geoffrey Urbanski; Philippe Rivereau; Laure Artru; Florence Fenollar; Didier Raoult; Xavier Puéchal
Journal:  Chest       Date:  2012-06       Impact factor: 9.410

7.  Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei.

Authors:  Florence Fenollar; Pierre-Edouard Fournier; Catherine Robert; Didier Raoult
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

8.  Treatment of classic Whipple's disease: from in vitro results to clinical outcome.

Authors:  Jean-Christophe Lagier; Florence Fenollar; Hubert Lepidi; Roch Giorgi; Matthieu Million; Didier Raoult
Journal:  J Antimicrob Chemother       Date:  2013-08-14       Impact factor: 5.790

9.  Tropheryma whipplei in patients with pneumonia.

Authors:  Sabri Bousbia; Laurent Papazian; Jean Pierre Auffray; Florence Fenollar; Claude Martin; Wenjun Li; Laurent Chiche; Bernard La Scola; Didier Raoult
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

10.  Widespread colonization of the lung by Tropheryma whipplei in HIV infection.

Authors:  Catherine Lozupone; Adela Cota-Gomez; Brent E Palmer; Derek J Linderman; Emily S Charlson; Erica Sodergren; Makedonka Mitreva; Sahar Abubucker; John Martin; Guohui Yao; Thomas B Campbell; Sonia C Flores; Gail Ackerman; Jesse Stombaugh; Luke Ursell; James M Beck; Jeffrey L Curtis; Vincent B Young; Susan V Lynch; Laurence Huang; George M Weinstock; Kenneth S Knox; Homer Twigg; Alison Morris; Elodie Ghedin; Frederic D Bushman; Ronald G Collman; Rob Knight; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

View more
  2 in total

1.  Tropheryma whipplei detection by metagenomic next-generation sequencing in bronchoalveolar lavage fluid: A cross-sectional study.

Authors:  Minmin Lin; Kongqiu Wang; Lidi Qiu; Yingjian Liang; Changli Tu; Meizhu Chen; Zhenguo Wang; Jian Wu; Yiying Huang; Cuiyan Tan; Qijiu Chen; Xiaobin Zheng; Jing Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-08-17       Impact factor: 6.073

2.  Genomic characterization of two metagenome-assembled genomes of Tropheryma whipplei from China.

Authors:  Zhongdong Lv; Yong Chen; Houqing Zhou; Zhonglin Chen; Qianru Yao; Jiali Ren; Xianglu Liu; Shuang Liu; Xiaomei Deng; Yingchen Pang; Weijun Chen; Huiling Yang; Ping Xu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-16       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.